Updates are available Correction dated 2025-07-07
Click to view Correction: https://doi.org/10.1038/s43587-025-00931-0
-
Authors
Saloner, Rowan https://orcid.org/0000-0002-1351-6183
Staffaroni, Adam M. https://orcid.org/0000-0002-3903-9805
Dammer, Eric B. https://orcid.org/0000-0003-2947-7606
Johnson, Erik C. B. https://orcid.org/0000-0002-0604-2944
Paolillo, Emily W.
Wise, Amy
Heuer, Hilary W. https://orcid.org/0000-0002-3776-1685
Forsberg, Leah K. https://orcid.org/0000-0003-4086-9598
Lario-Lago, Argentina
Webb, Julia D.
Vogel, Jacob W. https://orcid.org/0000-0001-6394-9940
Santillo, Alexander F. https://orcid.org/0000-0001-9717-0820
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
Kramer, Joel H.
Miller, Bruce L.
Li, Jingyao
Loureiro, Joseph https://orcid.org/0000-0001-7222-9160
Sivasankaran, Rajeev https://orcid.org/0000-0003-3917-0181
Worringer, Kathleen A.
Seyfried, Nicholas T. https://orcid.org/0000-0002-4507-624X
Yokoyama, Jennifer S. https://orcid.org/0000-0001-7274-2634
Spina, Salvatore https://orcid.org/0000-0003-3570-9143
Grinberg, Lea T. https://orcid.org/0000-0002-6809-0618
Seeley, William W. https://orcid.org/0000-0003-1410-2027
VandeVrede, Lawren https://orcid.org/0000-0002-8304-6711
Ljubenkov, Peter A.
Bayram, Ece https://orcid.org/0000-0002-6875-4242
Bozoki, Andrea
Brushaber, Danielle https://orcid.org/0009-0007-0543-0228
Considine, Ciaran M.
Day, Gregory S. https://orcid.org/0000-0001-5133-5538
Dickerson, Bradford C. https://orcid.org/0000-0002-5958-3445
Domoto-Reilly, Kimiko https://orcid.org/0000-0002-7396-1633
Faber, Kelley
Galasko, Douglas R. https://orcid.org/0000-0001-6195-3241
Gendron, Tania https://orcid.org/0000-0002-7335-2627
Geschwind, Daniel H. https://orcid.org/0000-0003-2896-3450
Ghoshal, Nupur https://orcid.org/0000-0002-6680-6731
Graff-Radford, Neill
Hales, Chadwick M.
Honig, Lawrence S. https://orcid.org/0000-0002-9703-2265
Hsiung, Ging-Yuek R. https://orcid.org/0000-0002-8017-0856
Huey, Edward D.
Kornak, John
Kremers, Walter
Lapid, Maria I. https://orcid.org/0000-0002-1163-5584
Lee, Suzee E.
Litvan, Irene https://orcid.org/0000-0002-3485-3445
McMillan, Corey T. https://orcid.org/0000-0002-7581-6405
Mendez, Mario F. https://orcid.org/0000-0001-6441-7989
Miyagawa, Toji
Pantelyat, Alexander https://orcid.org/0000-0002-6427-7485
Pascual, Belen https://orcid.org/0000-0002-4467-7406
Masdeu, Joseph
Paulson, Henry L.
Petrucelli, Leonard
Pressman, Peter https://orcid.org/0000-0003-1760-1286
Rademakers, Rosa
Ramos, Eliana Marisa
Rascovsky, Katya
Roberson, Erik D. https://orcid.org/0000-0002-1810-9763
Savica, Rodolfo
Snyder, Allison https://orcid.org/0000-0002-1857-928X
Sullivan, Anna Campbell
Tartaglia, M. Carmela https://orcid.org/0000-0002-5944-8497
Vandebergh, Marijne https://orcid.org/0000-0001-9645-2615
Boeve, Brad F. https://orcid.org/0000-0002-4153-8187
Rosen, Howie J.
Rojas, Julio C.
Boxer, Adam L.
Casaletto, Kaitlin B.
,
-
Funding
Funding for this research was provided by:
Alzheimer's Association (AARF-23-1145318, AARF-22-974065, AARG-20-683875)
American Academy of Neurology
American Brain Foundation
Association for Frontotemporal Degeneration
U.S. Department of Health & Human Services | NIH | National Institute on Aging (K23AG061253, R01AG032289, AG019724, P30 AG062422, K23AG073514, AG016976, AG058233, U19AG063911, U01AG045390, U19AG063911, U01AG045390, AG032306, K24AG045333, K23AG059888, U19AG063911, AG038791)
Larry L. Hillblom Foundation (2018-A-025-FEL, 2018-A-006-NET)
Vetenskapsrådet (2022-00775)
Knut och Alice Wallenbergs Stiftelse (2022-0231)
Hjärnfonden (FO2021-0293)
Swedish Parkinson's Disease Association | Parkinsonfonden (1412/22)
Cure Alzheimer's Fund
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (U54NS092089, U54NS092089, U54NS092089)
- License Information
-
More Information
Article History
Received: 22 March 2024
Accepted: 17 April 2025
First Online: 16 May 2025
Change Date: 7 July 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43587-025-00931-0
Competing interests
: A.M.S. received research support from the NIA/NIH, the Bluefield Project to Cure FTD, and the Larry L. Hillblom Foundation. He has provided consultation to Alector, Lilly, Passage Bio and Takeda. L.K.F. receives research support from the NIH. O.H. has received research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. J.S.Y. receives research support from the NIH. P.A.L. is a site primary investigator for clinical trials by Alector, AbbVie and Woolsey. He serves as an advisor for Retrotrope. He receives research and salary support from the NIH–NIA and the Alzheimer’s Association-Part the Cloud partnership. E.B. receives research support from the NIH and Lewy Body Dementia Association. B.C.D. is a consultant for Acadia, Alector, Arkuda, Biogen, Denali, Eisai, Genentech, Lilly, Merck, Novartis, Takeda and Wave Lifesciences; receives royalties from Cambridge University Press, Elsevier and Oxford University Press; and receives grant funding from the NIA, the National Institute of Neurological Disorders and Stroke, the National Institute of Mental Health and the Bluefield Foundation. K.D.-R. receives research support from the NIH and serves as an investigator for a clinical trial sponsored by Lawson Health Research Institute. K.F. receives research support from the NIH. N.G. has participated or is currently participating in clinical trials of anti-dementia drugs sponsored by Bristol Myers Squibb, Eli Lilly/Avid Radiopharmaceuticals, Janssen Immunotherapy, Novartis, Pfizer, Wyeth, SNIFF (The Study of Nasal Insulin to Fight Forgetfulness) and the A4 (The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease) trial; and receives research support from Tau Consortium, the Association for Frontotemporal Dementia and the NIH. N.G.-R. receives royalties from UpToDate and has participated in multicenter therapy studies by sponsored by Biogen, TauRx, and Lilly; and receives research support from the NIH. C.M.H. is a Site PI or SubI for several industry (Alector, Janssen, Biogen, Cogito Tx) sponsored clinical trials with funding through Emory Office of Sponsored Programs. L.S.H. receives research funding from Abbvie, Acumen, Alector, Biogen, BMS, Eisai, Genentech/Roche, Janssen/J&J, Transposon, UCB, Vaccinex; and receives consulting fees from Biogen, Cortexyme, Eisai, Medscape, Prevail/Lilly. G.-Y.R.H. has served as an investigator for clinical trials sponsored by AstraZeneca, Eli Lilly and Roche/Genentech; and he receives research support from the Canadian Institutes of Health Research and the Alzheimer Society of British Columbia. E.D.H. receives research support from the NIH. J. Kornak has provided expert witness testimony for Teva Pharmaceuticals in Forest Laboratories Inc. et al. v Teva Pharmaceuticals USA, Inc., case numbers 1:14-cv-00121 and 1:14-cv-00686 (D. Del. filed 31 January 2014 and 30 May 2014 regarding the drug Memantine) and for Apotex/HEC/Ezra in Novartis AG et al. v Apotex Inc., case number 1:15-cv-975 (D. Del. filed 26 October 2015 regarding the drug Fingolimod); he has also given testimony on behalf of Puma Biotechnology in Hsingching Hsu et al. v Puma Biotechnology, Inc., et al. 2018 regarding the drug neratinib; and he receives research support from the NIH. W.K. receives research funding from AstraZeneca, Biogen, Roche, the Department of Defense and the NIH. M.I.L. receives research support from the NIH. The research of I.L. is supported by the National Institutes of Health grants 2R01AG038791-06A, U01NS100610, U01NS80818, R25NS098999; U19 -1 and 1R21NS114764-01A1; the Michael J Fox Foundation, Parkinson Foundation, Lewy Body Association, CurePSP, Roche, Abbvie, Biogen, Centogene. EIP-Pharma, Biohaven Pharmaceuticals, Novartis, Brain Neurotherapy Bio and United Biopharma SRL–UCB. She is a scientific advisor for Amydis and Rossy Center for Progressive Supranuclear Palsy University of Toronto. She receives her salary from the University of California San Diego and as Chief Editor of Frontiers in Neurology. C.T.M. receives funding from NIH and Penn Institute on Aging. M.F.M. receives research support from the NIH. A.P. receives research support from the NIH (U01 NS102035; K23 ). H.L.P. receives research support from the NIH. L.P. receives research support from the NIH. E.M.R. receives research support from the NIH. K.R. receives research support from the NIH. E.D.R. has received research support from the NIH, the Bluefield Project to Cure Frontotemporal Dementia, the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation, the BrightFocus Foundation, and Alector; has served as a consultant for AGTC and on a data monitoring committee for Lilly; and owns intellectual property related to tau and progranulin. R.S. receives support from the NIA, the National Institute of Neurological Disorders and Stroke, the Parkinson’s Disease Foundation and Acadia Pharmaceuticals. M.C.T. has served as an investigator for clinical trials sponsored by Biogen, Avanex, Green Valley, Roche/Genentech, Bristol Myers Squibb, Eli Lilly/Avid Radiopharmaceuticals and Janssen. She receives research support from the Canadian Institutes of Health Research. B.F.B. has served as an investigator for clinical trials sponsored by Alector, Biogen, Transposon and Cognition Therapeutics. He serves on the Scientific Advisory Board of the Tau Consortium which is funded by the Rainwater Charitable Foundation. He receives research support from NIH. H.J.R. has received research support from Biogen Pharmaceuticals, has consulting agreements with Wave Neuroscience, Ionis Pharmaceuticals, Eisai Pharmaceuticals and Genentech, and receives research support from the NIH and the state of California. J.C.R. receives research support from the NIH and is a site principal investigator for clinical trials sponsored by Eli Lilly and Eisai. A.L.B. receives research support from the NIH, the Tau Research Consortium, the Association for Frontotemporal Degeneration, Bluefield Project to Cure Frontotemporal Dementia, Corticobasal Degeneration Solutions, the Alzheimer’s Drug Discovery Foundation and the Alzheimer’s Association. He has served as a consultant for Aeovian, AGTC, Alector, Arkuda, Arvinas, Boehringer Ingelheim, Denali, GSK, Life Edit, Humana, Oligomerix, Oscotec, Roche, TrueBinding, Wave, Merck and received research support from Biogen, Eisai and Regeneron. The other authors declare no competing interests.
